As the global markets react positively to the recent U.S.-China tariff suspension, Asian equities have shown resilience with Chinese stocks rallying on hopes of reduced trade tensions. In such a climate, identifying growth companies with substantial insider ownership can be particularly appealing, as high insider stakes often signal confidence in a company's future prospects and alignment with shareholder interests.
Top 10 Growth Companies With High Insider Ownership In Asia
| Name | Insider Ownership | Earnings Growth |
| Sineng ElectricLtd (SZSE:300827) | 36% | 26.8% |
| Nanya New Material TechnologyLtd (SHSE:688519) | 11% | 63.1% |
| Schooinc (TSE:264A) | 26.6% | 68.9% |
| Global Tax Free (KOSDAQ:A204620) | 20.8% | 35.1% |
| Fulin Precision (SZSE:300432) | 13.6% | 44.2% |
| Oscotec (KOSDAQ:A039200) | 21.1% | 85.9% |
| Zhejiang Leapmotor Technology (SEHK:9863) | 15.6% | 60.7% |
| giftee (TSE:4449) | 34.5% | 63.7% |
| Suzhou Sunmun Technology (SZSE:300522) | 35.4% | 77.7% |
| Techwing (KOSDAQ:A089030) | 18.8% | 65% |
We're going to check out a few of the best picks from our screener tool.
MIXUE Group (SEHK:2097)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: MIXUE Group operates in the production and sale of fruit drinks, tea drinks, ice cream, and coffee products both in Mainland China and internationally, with a market cap of HK$195.69 billion.
Operations: The company's revenue is primarily derived from franchise and related services (CN¥620.05 million), sales of goods (CN¥23.45 billion), and sales of equipment (CN¥756.37 million).
Insider Ownership: 28.8%
MIXUE Group, recently completing an HKD 3.45 billion IPO, demonstrates strong growth potential with earnings forecasted to grow at 16.1% annually, outpacing the Hong Kong market's average. Despite high share price volatility and moderate revenue growth projections of 13.4%, the company's high insider ownership aligns interests with shareholders. Recent changes in share capital structure following a full exercise of the over-allotment option reflect strategic adjustments post-IPO to support its expansion ambitions in Asia.
- Click to explore a detailed breakdown of our findings in MIXUE Group's earnings growth report.
- Upon reviewing our latest valuation report, MIXUE Group's share price might be too optimistic.
Akeso (SEHK:9926)
Simply Wall St Growth Rating: ★★★★★★
Overview: Akeso, Inc., a biopharmaceutical company, focuses on the research, development, manufacturing, and commercialization of antibody drugs with a market cap of approximately HK$74.99 billion.
Operations: The company's revenue is primarily derived from the research, development, production, and sale of biopharmaceutical products, totaling CN¥2.12 billion.
Insider Ownership: 19%
Akeso's high insider ownership aligns with its growth trajectory, as the company is trading at a significant discount to its estimated fair value. Akeso's revenue is expected to grow rapidly at 29.6% annually, outpacing the Hong Kong market average. The company's recent approval of ivonescimab for NSCLC treatment and FDA approval of penpulimab highlight strong innovation capabilities despite recent earnings decline, positioning Akeso for potential profitability and robust market presence in oncology therapeutics.
- Navigate through the intricacies of Akeso with our comprehensive analyst estimates report here.
- According our valuation report, there's an indication that Akeso's share price might be on the expensive side.
InnoCare Pharma (SEHK:9969)
Simply Wall St Growth Rating: ★★★★★☆
Overview: InnoCare Pharma Limited is a biopharmaceutical company focused on discovering, developing, and commercializing drugs for cancer and autoimmune diseases in China, with a market cap of HK$21.34 billion.
Operations: The company's revenue is primarily derived from its pharmaceuticals segment, totaling CN¥1.01 billion.
Insider Ownership: 21.4%
InnoCare Pharma benefits from high insider ownership, supporting its rapid growth trajectory with revenue expected to increase by 23.7% annually, surpassing the Hong Kong market average. The company is advancing several promising therapies, including Soficitinib for vitiligo and Mesutoclax for lymphoma, both receiving regulatory recognition in China. Despite current unprofitability and past losses of C¥440.63 million, InnoCare trades below estimated fair value, driven by a strong pipeline and potential future profitability in the biotech sector.
- Delve into the full analysis future growth report here for a deeper understanding of InnoCare Pharma.
- The valuation report we've compiled suggests that InnoCare Pharma's current price could be inflated.
Seize The Opportunity
- Embark on your investment journey to our 619 Fast Growing Asian Companies With High Insider Ownership selection here.
- Ready For A Different Approach? AI is about to change healthcare. These 21 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if InnoCare Pharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com